HomeP8A • SGX
add
Cordlife Group Ltd
Previous close
$0.14
Day range
$0.14 - $0.14
Year range
$0.12 - $0.33
Market cap
36.92M SGD
Avg Volume
14.89K
P/E ratio
-
Dividend yield
-
Primary exchange
SGX
Market news
Financials
Income Statement
Revenue
Net income
| (SGD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 9.46M | 13.52% |
Operating expense | 10.36M | 1.77% |
Net income | -5.55M | -11.80% |
Net profit margin | -58.72 | 1.51% |
Earnings per share | — | — |
EBITDA | -3.89M | 26.69% |
Effective tax rate | -29.22% | — |
Balance Sheet
Total assets
Total liabilities
| (SGD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 51.32M | -16.06% |
Total assets | 201.76M | -7.08% |
Total liabilities | 97.28M | -1.42% |
Total equity | 104.48M | — |
Shares outstanding | 256.31M | — |
Price to book | 0.34 | — |
Return on assets | -6.06% | — |
Return on capital | -11.44% | — |
Cash Flow
Net change in cash
| (SGD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -5.55M | -11.80% |
Cash from operations | -751.00K | -1,606.82% |
Cash from investing | -6.59M | 50.34% |
Cash from financing | -557.00K | -106.95% |
Net change in cash | -8.36M | -45.26% |
Free cash flow | -1.32M | — |
About
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
CEO
Founded
May 2, 2001
Website
Employees
111
